China market entry for silver economy brands begins with a definition
The silver economy is the sum of economic activity that supplies products and services to people aged 60 and over, plus the preparation younger households make for old age. That is not a marketing construct — the State Council's General Office defined it in exactly those terms in Guobanfa 2024 No. 1, the first national policy document devoted to the sector, which paired "serving the old" with "preparing for old age" across 26 measures in four areas (Guobanfa 2024 No. 1). The double definition matters to a foreign brand because it doubles the addressable buyer. The user may be a 78-year-old with reduced mobility; the payer is frequently a 48-year-old daughter, or a 55-year-old buying supplements for herself under the preparation half of the policy. Brands that price and package only for the patient miss most of the transactions in the category.
The one demand curve in China that cannot flatten
A demographic demand curve is a market whose customer count was fixed by births and deaths decades before the product exists. China's population fell by 3.39 million in 2025 to 1,404.89 million, with 7.92 million births against 11.31 million deaths — a natural growth rate of minus 2.41 per thousand (NBS 2025 Statistical Communiqué). Inside that shrinking total, the 60-plus group reached 323.38 million at 23.0 percent, and the 65-plus group 223.65 million at 15.9 percent. Now compare the pool every other consumer category competes for: 976 million online shoppers, up 0.1 percent in six months at 86.9 percent penetration (CNNIC, 56th Statistical Report). One audience grows by arithmetic; the other has stopped. For an overseas brand allocating its first Chinese marketing budget, that asymmetry is the single most useful planning fact on the table.
Policy has already committed the money
A policy-anchored market is one where the state has published a size target, which tells you the direction of travel even when the current number is modest. Government estimates put the silver economy at roughly RMB 7 trillion today, about 6 percent of GDP, and project around RMB 30 trillion by 2035 — roughly 10 percent of GDP (State Council policy explainer, 2024). The same document commits to around 10 high-level silver-economy industrial parks in the Beijing-Tianjin-Hebei, Yangtze Delta, Greater Bay and Chengdu-Chongqing regions, and names the product categories it wants improved: functional foods suited to chewing and swallowing difficulties, hearing aids, orthotics, smart wheelchairs, nursing beds and home monitoring devices. Two adjacent sectors show what happens when that intent meets demand. Rehabilitation aids reached an industry scale of RMB 730 billion with about 240,000 market entities by the end of 2025 (Ministry of Civil Affairs). Special medical purpose foods grew from RMB 7 billion in 2020 to RMB 23 billion in 2024, a compound annual rate above 25 percent (SAMR).
The import gap is breadth, not price
An assortment gap is a market where the domestic catalogue is complete in volume but thin in variety, so imports succeed on formats rather than on prestige. China circulates more than 10,000 rehabilitation-aid products across 773 above-scale manufacturers, against roughly 40,000 on the international market (Ministry of Civil Affairs, 2026). That ratio is the whole opportunity in one line. Chinese buyers no longer lack a wheelchair; they lack the specific wheelchair, the texture-modified food that a dysphagia patient will actually swallow, the anti-decubitus surface, the home sleep-apnoea device with a Mandarin interface. The same pattern shows in special medical purpose foods, where domestic registration share climbed from 49 percent in 2020 to 88 percent in 2025 — the mainstream clinical categories are now supplied locally, and imports are being pushed toward rare conditions, novel formats and premium positioning (SAMR). A brand arriving with a generic version of a category China already makes will lose on price. A brand arriving with a format that does not yet exist here owns the shelf.
Three regulatory tracks decide whether the product can be sold at all
A regulatory track is the route a product must clear before it may be lawfully sold, and for this category there are four, with radically different timelines. Choosing the wrong track is the most expensive mistake available to a foreign brand, because the registration dossier has to be rebuilt from scratch if the classification was wrong.
| Track | Authority and instrument | What the dossier needs | Practical timeline |
|---|---|---|---|
| Health food (blue hat) | SAMR — registration, or filing for vitamin and mineral products on the raw-material catalogue | Function claim limited to the permitted catalogue; safety and function evaluation; manufacturing site in good standing | Long, and competitive: 14 imported registrations cleared in 2025 against 2,224 domestic |
| Special medical purpose food | SAMR — product registration, with clinical trial guidance by category | Clinical evidence, formula justification, and compliance with the 2025 national standards | Long; 330 products registered in total, with 35 on the priority review channel |
| Medical device | NMPA — Class I filing, Class II and III registration | Technical requirements, type testing, clinical evaluation, a local agent and quality system documentation | Class II typically 12 to 24 months; Class III longer |
| Ordinary adaptive goods | No product registration — standards, labelling and advertising law still apply | GB standard conformity, Chinese labelling, no medical claims | Weeks to months |
The funnel is narrower than the demand. In 2025, SAMR's special food division reported 2,224 domestic registered health foods approved against 14 imported ones, and 3,783 domestic filings against 36 imported filings (China Food Safety News interview with SAMR, 2025). Fourteen approvals across the entire world, in a market of 323 million older consumers, is not a shortage of demand. It is the shape of the gate.
The channel itself may need a licence
A distribution licence is the authorisation a Chinese reseller needs before it may trade a regulated product — separate from the product's own registration. For devices the obligation sits with the seller, not only the brand: under the Medical Device Supervision and Administration Regulation, Class II distribution requires a filing with the municipal drug regulator, and Class III requires a distribution licence decided within 20 working days and valid for five years (State Council Order 739). Article 43 carries the exception that matters most for a brand building a local presence: a registration holder selling its own registered device needs neither a distribution licence nor a filing, provided it meets the operating conditions. The practical consequence is that your route decision also decides who must be licensed — a third-party distributor, a bonded operator acting as seller of record, or your own Chinese entity once it holds the registration. Ask to see the licence before you discuss the purchase order.
The bonded lane is how you test before you register
Cross-border retail import is a customs regime that treats goods bought by individuals from overseas as personal-use items rather than as general-trade imports. Under Shang Cai Fa 486 of 2018, products sold this way are supervised as personal items and are not subject to the first-import licence, registration or filing requirements that general trade demands — the seller must instead present a risk notice and give the buyer access to a Chinese electronic label before the order is confirmed (Shang Cai Fa 486 of 2018). The economic frame is equally clear: zero duty and value-added and consumption taxes at 70 percent of the statutory amount within the RMB 5,000 per-order and RMB 26,000 per-person annual limits (Cai Guan Shui 49 of 2018). This is why the category leans on the bonded model. Health and medical products accounted for 13.7 percent of cross-border retail imports in 2025, down 1.7 percentage points year on year — a decline that tracks domestic substitution in mainstream categories rather than any loss of appetite (GACC 2025 cross-border statistics). The imports that are still growing are the ones the domestic catalogue cannot match.
Where to test, and what evidence to bring back
A test market is a bounded launch whose purpose is to produce decision-grade evidence, not revenue. For this category the evidence that matters is repeat purchase among households rather than units shifted, because elder-care products are bought in cycles and a one-off spike tells you nothing. Pick two bonded ports, not five: one northern (Tianjin or Qingdao) and one eastern (Shanghai or Ningbo) reads both the older, colder-climate north and the higher-income Yangtze Delta at half the inventory cost. Hold the price at full value, run one full season, and record the household repeat rate, the share of orders placed by someone other than the end user, and the after-sales reason codes. Those three numbers tell you whether to fund a registration dossier — and which track it belongs on.
How GOODSINFINITE supports silver-economy brands
GOODSINFINITE TRADE LIMITED acts as the importer of record and bonded-fulfilment operator for overseas brands entering mainland China, and maps the regulatory track before any stock moves. From Hong Kong we classify the product against the four tracks above, run the bonded pilot through warehouses in Tianjin, Shanghai, Ningbo, Guangzhou and Qingdao, and hand back the household-level evidence a registration decision needs. Where the dossier is the right answer, we sequence it; where the bonded lane is the faster answer, we keep the brand selling while it is prepared. The entry framework behind this piece is set out in our China market entry guide, with terminology in the glossary.
FAQ
Sources
- National Bureau of Statistics — 2025 Statistical Communiqué: 323.38 million aged 60-plus, 23.0 percent of population
- State Council General Office — Guobanfa 2024 No. 1, Opinions on Developing the Silver Economy and Improving the Wellbeing of Older People
- State Council policy explainer — silver economy at about RMB 7 trillion and 6 percent of GDP, projected near RMB 30 trillion by 2035
- SAMR — special medical purpose food: domestic registration share 49 to 88 percent, market RMB 7 billion to 23 billion
- Ministry of Civil Affairs — rehabilitation aids industry scale passes RMB 730 billion, 240,000 market entities
- Shang Cai Fa 486 of 2018 — regulation of cross-border e-commerce retail imports
Related reading
- China market research for foreign brands: what desk data cannot tell you
- China health food registration and the blue hat
- China medical device classification and registration
- Test before you commit: the China market-entry pilot ladder
- China market entry by region: where demand sits
- Glossary of China import and e-commerce terms